Genmab — December 2025
-
Syntes Genmab har holdt lav profil på Acasunlimab, men blev dog nævnt igår. Halvering af ORR (15,6 vs 30%) i PH3 popl. men stadigvæk en imponerende 12m OS (64% vs 69%). De nyeste data indeholder alle pts så inklusiv de pts som have discontinuation grundet forsøgsdesign. Den gl. ORR på 30% var unconfirmed og confirmed var 17% vs ny 15.6%. Det bliver ikke på ORR ACA skal gøre sig gældende men på OS, hvilket også er det vigtigst.
-
Godmorgen

-
Bispecifics Are Shifting the Treatment Paradigm in Follicular Lymphoma: Highlights From ASH 2025 https://www.oncologynewscentral.com/video/lymphoma/bispecifics-are-shifting-the-treatment-paradigm-in-follicular-lymphoma-highlights-from-ash-2025
-
lahn....Den slags var på foranledning af Mioklubben. Her stoppede jeg vist traditionen i 2015.

-
Hvis man trænger til lidt underholdning, så er der jo altid Saxos vilde forudsigelser.https://www.home.saxo/da-dk/insights/news-and-research/thought-leadership/outrageous-predictions
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind